Formycon Expands to Brazil With Ranivisio: Biosimilar Market in Latin America Gains Importance

Formycon AG is a turnaround candidate from the small-cap sector. On June 5th, the stock can boast a gap-up. The trigger is the approval of the Lucentis biosimilar FYB201 in Brazil, reported early this morning, following the recent announcement of the market launch of the Stelara2 biosimilar FYB202/OtulfiTM in partnership with Fresenius Kabi in Canada. The Brazilian regulatory authority ANVISA has granted market approval for the Lucentis biosimilar FYB201, marketed under the name Ranivisio. FYB201 is already approved in 21 countries worldwide,...